pubmed.ncbi.nlm.nih.gov

Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment - PubMed

Clinical Trial

Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment

Will Foster et al. J Thromb Thrombolysis. 2010 May.

Abstract

Tumour necrosis factor alpha (TNF-alpha) and interlekin-6 (IL-6) are key inflammatory cytokines in the pathogenesis of rheumatoid arthritis (RA), a disease also associated with endothelial perturbation and increased serum levels of adhesion molecules. As relationships between these processes and molecules are unclear, we tested the hypotheses (a) that TNF-alpha and IL-6 are linked to endothelial activation/damage and levels of soluble adhesion molecules, and (b) that intensive anti-inflammatory treatment improves levels of these indices. We recruited 66 patients with RA, 48 community controls (CC), and 25 disease controls (DC). Plasma TNF-alpha and IL-6 were compared to markers of vascular biology (vWF, sE-sel), soluble adhesion molecules (sICAM, sVCAM) and routine inflammatory markers (CRP and ESR). Blood was obtained at baseline and at 1 week and again 4 weeks after anti-inflammatory treatment in a subgroup of 29 patients with RA. With the exception of sE-selectin, RA patients had increased levels of all plasma markers compared to the HCs, whilst levels in the DCs were largely intermediate between RA and the CCs. Within the RA group, sEsel correlated with both CRP and ESR whilst TNF-alpha correlated with sVCAM (all r > 0.32, P < 0.01). After 1 week of combined anti-inflammatory therapy, only CRP, ESR, sEsel and sVCAM were significantly reduced (all P < 0.05). In RA, endothelial activation (as sEsel) correlates with classical markers of inflammation and is reduced by intensive anti-inflammatory medications.

PubMed Disclaimer

Cited by

Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity.
Ristić GG, Subota V, Lepić T, Stanisavljević D, Glišić B, Ristić AD, Petronijević M, Stefanović DZ. Ristić GG, et al. PLoS One. 2015 Aug 6;10(8):e0130462. doi: 10.1371/journal.pone.0130462. eCollection 2015. PLoS One. 2015. PMID: 26247590 Free PMC article.
Correlation Between Tumor Necrosis Factor-α Levels, Free Fatty Acid Levels, and Soluble Vascular Cell Adhesion Molecule-1 Levels in Rheumatoid Arthritis Patients.
Nasriati F, Hidayat R, Budiman B, Rinaldi I. Nasriati F, et al. Open Rheumatol J. 2018 Jul 19;12:86-93. doi: 10.2174/1874312901812010086. eCollection 2018. Open Rheumatol J. 2018. PMID: 30123370 Free PMC article.
Molecular pathobiology of scleritis and its therapeutic implications.
Das UN. Das UN. Int J Ophthalmol. 2020 Jan 18;13(1):163-175. doi: 10.18240/ijo.2020.01.23. eCollection 2020. Int J Ophthalmol. 2020. PMID: 31956585 Free PMC article. Review.
The erythrocyte sedimentation rate in HIV: a neglected parameter?
Lowe DM. Lowe DM. AIDS. 2010 Nov 27;24(18):2773-5. doi: 10.1097/QAD.0b013e32833ef5d7. AIDS. 2010. PMID: 20827163 Free PMC article. No abstract available.
Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease.
de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, Posthumus MD. de Groot L, et al. Arthritis Res Ther. 2011;13(6):R205. doi: 10.1186/ar3538. Epub 2011 Dec 14. Arthritis Res Ther. 2011. PMID: 22168993 Free PMC article.

References

1. J Hum Hypertens. 2004 Mar;18(3):139-85 - PubMed
1. Am J Pathol. 1992 May;140(5):1055-60 - PubMed
1. J Hypertens. 2001 Jun;19(6):1139-47 - PubMed
1. Arterioscler Thromb. 1993 Mar;13(3):407-14 - PubMed
1. J Pathol. 2008 Jan;214(2):149-60 - PubMed

Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment - PubMed